Unstable non-obstructive atherosclerotic plaques account for a significant proportion of acute coronary syndromes, especially when they get inflamed. Unfortunately, most of such plaques cannot be identified on non-invasive testing which rely on detection of flow-limiting stenosis. [1] [2] [3] While certain inflammatory biomarkers like C-reactive protein increase risk of a major cardiovascular event, 4,5 they are considered relatively non-specific to precisely detect actual inflammatory activity at the level of an individual coronary artery. In recent years, there is an increased understanding that the adipose tissue adjacent to the coronary arteries and the heart is an active area, generating many inflammatory agents within the local milieu. This is suspected of promoting progression of atherosclerotic changes within the coronary arteries, with resultant major adverse cardiac events. Coronary computed tomography angiography (CTA) is an established and highly sensitive non-invasive technique to detect obstructive and non-obstructive coronary artery disease (CAD).
Unstable non-obstructive atherosclerotic plaques account for a significant proportion of acute coronary syndromes, especially when they get inflamed. Unfortunately, most of such plaques cannot be identified on non-invasive testing which rely on detection of flow-limiting stenosis. [1] [2] [3] While certain inflammatory biomarkers like C-reactive protein increase risk of a major cardiovascular event, 4, 5 they are considered relatively non-specific to precisely detect actual inflammatory activity at the level of an individual coronary artery. In recent years, there is an increased understanding that the adipose tissue adjacent to the coronary arteries and the heart is an active area, generating many inflammatory agents within the local milieu. This is suspected of promoting progression of atherosclerotic changes within the coronary arteries, with resultant major adverse cardiac events. Coronary computed tomography angiography (CTA) is an established and highly sensitive non-invasive technique to detect obstructive and non-obstructive coronary artery disease (CAD). 6 However, it has not been well-studied as a technique to detect inflammatory changes (or its impact on future coronary events) in the surrounding fatty tissue. Recently, a new index, fat attenuation index (FAI), has been developed to detect and quantify changes in perivascular fat resulting from ongoing inflammation, using clinically acquired coronary CTA. 7 It appears that the inflamed coronary arteries release signals into the surrounding adipose tissue, which results in inhibition of local adipogenesis. This ultimately alters perivascular fat composition adjacent to the inflamed coronaries and shifts the attenuation on coronary CTA from the lipid to the aqueous phase. Perivascular FAI captures these inflammation-induced changes on routine coronary CTA, resulting in earlier detection of coronary inflammation. However, the index's utility for clinical risk stratification was uncertain, prompting the CRISP-CT study, which tests the association between FAI and future fatal myocardial infarctions. These findings could be of potential significance because almost 50% of the myocardial infarctions occur in the absence of substantial coronary stenosis. 1 The CRISP-CT study also highlights the importance of diligent translational research which resulted in the development of an imaging biomarker in a basic science realm, with subsequent application, and validation in a large human cohort across continents. can be utilized to detect improvements in the local inflammatory milieu following development of novel anti-inflammatory therapies. From a broadly relevant clinical perspective, FAI can be targeted to intensify existing therapies or developing newer therapies (which in turn could further attenuate risk of future coronary events) could be tested as part of well-designed prospective randomized studies. Such studies could prove conclusively whether FAI could serve as a marker of personalized medicine in this secondary prevention setting. Also, an important next step would be to operationalize this marker for routine clinical use.
